Carlos Ferrario

Carlos Ferrario

Carlos M. Ferrario, MD, is a cardiologist whose research has advanced understanding and treatment of high blood pressure and vascular disease. A graduate of the University of Buenos Aires Medical School in 1963, Dr. Ferrario pursued postgraduate training in cardiology at the University of Goteborg and the Karolinska Institute in Sweden between 1964 and 1966 and then joined Dr. Irvine H. Page, a pioneer in hypertension research, at The Cleveland Clinic Foundation in 1966. Dr. Ferrario developed a premier program on the neural and endocrine causes of hypertension chairing the Department of Brain and Vascular Research of the Cleveland Clinic Foundation from 1984 to 1 992. He founded the Hypertension and Vascular Research Center at the Wake Forest University School of Medicine in 1992, serving as its Director until 2009.

Dr. Ferrario’s research identified the mechanisms of action of angiotensin in the brain through his discovery of the area postrema as a site for the action of the hormone (7, 8), the role of the heart in the development of arterial hypertension (10, 15, 18), and discovered new endocrine pathways leading to the formation and action of angiotensin peptides. Pioneering research in the renin-angiotensin system includes the discovery of the antihypertensive function of angiotensin-(1-7) (4-6, 17), the role of angiotensin converting enzyme 2 as a component of the opposing arm of the renin angiotensin system (3, 12), and the furthering of understanding as to how inhibitors of angiotensin converting enzyme and angiotensin receptor antagonists act on the body’s nervous and endocrine mechanisms to regulate blood pressure (5, 13, 16). His studies on the role of angiotensin II in the pathogenesis of atherosclerosis lead to increased recognition on the interaction between lipids and endocrine hormones in the evolution of atherosclerosis (11, 19). The newer studies identifying the function of angiotensin-(1-12) as a novel  tissue substrate forming angiotensin II directly by chymase rather than angiotensin converting enzyme (1, 2, 9, 14) are underscoring the important of species differences in characterizing the mechanisms accounting for the pathogenesis of heart and vascular disease.

Dr. Ferrario has published over 500 papers, 74 book chapters, and 5 books. He has mentored over 61 physicians, many of which have become major medical leaders in the USA, Japan, and Latin America.

Dr. Ferrario is a former Established Investigator and the recipient of the Harry Goldblatt Award from the American Heart Association. In 1998, Dr. Ferrario was presented with the Ignacio Chaves Centennial Gold Medal of Honor by the National University of Mexico, an internationally recognized veneration of excellence in Cardiology and research. The European Society of Hypertension awarded Dr. Ferrario the 1999 Hypertension Angiotensin II Investigator of the Year. He was recognized and selected as the 1999 recipient of the Wake Forest University School of Medicine Established Investigator in Clinical Science award. In addition, he was awarded the Robert Tigersted award from the American Society of Hypertension and the Lifetime Achievement Award from the Inter-American Society of Hypertension for his contributions to the field of hypertension research in 2001. Additional awards include the Corcoran Award from the AHA in 2007, and the R Tigersted and J Wright awards from the Finnish (2008) and Australian (2008) Societies of Hypertension, respectively. In 2009, he received the Novartis Award for Hypertension Research from the Council of High Blood Pressure Research, American Heart Association, the highest recognition of achievements awarded by any organization in the world.

He is a member and officer of numerous medical organizations including membership in the American Physiological Society since 1967, Immediate Past-President of the Inter- American Society of

Hypertension, Fellow of the American College of Cardiology, the Council for High Blood Pressure Research, the American Society of Hypertension, and the Southern Society for Clinical Investigation. Honorary memberships include Societies of Cardiology in Argentina, Brazil, Ecuador, Venezuela, Spain, and Mexico. Currently, he is the Founder and Immediate Past-Editor-in-Chief of Therapeutic Advances  in Cardiovascular Disease and a Member of the Editorial Board of several journals.

He is the Founder of the Consortium for Southeastern Hypertension Control (COSEHC™), an organization which has pioneered medical and educational efforts directed to reduce cardiovascular deaths in the South, serving as its President and Chief Executive Officer until 2008.

Literature Cited:

  1. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, and Ferrario CM. Chymase- dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One 6: e28501, 2011.
  2. Ahmad S, Varagic J, VonCannon JL, Groban L, Collawn JF, Dell'Italia LJ, and Ferrario CM. Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochem Biophys Res Commun 478: 559-564, 2016.
  3. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos- Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, and Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828, 2002.
  4. Ferrario CM. Angiotension-(1-7) and antihypertensive mechanisms. J Nephrol 11: 278-283, 1998.
  5. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 55: 445-452, 2010.
  6. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, and Dell'italia LJ. An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) 126: 461-469, 2014.
  7. Ferrario CM, Barnes KL, Diz DI, Block CH, and Averill DB. Role of area postrema pressor mechanisms in the regulation of arterial pressure. Can J Physiol Pharmacol 65: 1591-1597, 1987.
  8. Ferrario CM, Dickinson CJ, and McCubbin JW. Central vasomotor stimulation by angiotensin. Clin Sci 39: 239-245, 1970.
  9. Ferrario CM, and Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 125: 57-71, 2017.
  10. Ferrario CM, Page IH, and McCubbin JW. Increased cardiac output as a contributory factor in experimental renal hypertension in dogs. Circ Res 27: 799-810, 1970.
  11. Ferrario CM, and Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128, 2006.
  12. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, and Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43: 970-976, 2004.
  13. Iyer SN, Chappell MC, Averill DB, Diz DI, and Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31: 699-705, 1998.
  14. Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, and Ferrario CM. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 294: H2614-2618, 2008.
  15. Liard JF, Tarazi RC, Ferrario CM, and Manger WM. Hemodynamic and humoral characteristics of hypertension induced by prolonged stellate ganglion stimulation in conscious dogs. Circ Res 36: 455-464, 1975.
  16. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, and Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 14: 799-805, 1996.
  17. Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, and Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A 85: 4095-4098, 1988.
  18. Spech MM, Ferrario CM, and Tarazi RC. Cardiac pumping ability following reversal of hypertrophy and hypertension in spontaneously hypertensive rats. Hypertension 2: 75-82, 1980.
  19. Strawn WB, Chappell MC, Dean RH, Kivlighn S, and Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101: 1586- 1593, 2000.